Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report

Bacci, Gaetano; Ferrari, Stefano; Bertoni, Franco; Ruggieri, Pietro; Picci, Piero; Longhi, Alessandra; Casadei, Roberto; Fabbri, Nicola; Forni, Cristiana; Versari, Michela; Campanacci, Mario

doi:10.1200/jco.2000.18.24.4016

Cited by 381 publications

(264 citation statements)

References 40 publications

Supporting

Mentioning

240

Contrasting

Unclassified

Order By: Relevance

“…Arteriography afforded a useful serial assessment of reduction in tumor neovascularity and greatly assisted in surgical planning for either limb preservation or amputation. Our rate of limb preservation (92%) is comparable if not better than others reported in the literature [1,3]. Two patients had local recurrence at a rate of 3.7%.…”

Section: Discussionsupporting

confidence: 84%

“…By using serial arteriography to monitor tumor response and individualize the duration of neoadjuvant therapy, we achieved a 77% rate of good histologic response. We deduce that our high rate of good response likely translated into an exceptional survival rate as opposed to more traditional protocols which prescribe a set number of preoperative cycles and result in survival rates in the 70% range [1,3,4,7,19,21,24,[42][43][44]52].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intraarterial Chemotherapy for Extremity Osteosarcoma and MFH in Adults

Hugate

Wilkins

Kelly

et al. 2008

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

The neoadjuvant treatment of osteosarcoma using intravenous agents has resulted in survival rates of 55% to 77% [3,5,6,20,22,35]. We designed a neoadjuvant chemotherapy protocol using combined intraarterial and intravenous agents to treat high-grade osteosarcoma and malignant fibrous histiocytoma of bone in an attempt to improve survival. We report the results of treating 53 adults (age 18-77 years) diagnosed with nonmetastatic extremity osteosarcoma or malignant fibrous histiocytoma. Preoperative chemotherapy consisted of intravenous doxorubicin followed by intraarterial cisplatinum administered repetitively every 3 weeks for three to five cycles, depending on tumor response assessed by serial arteriography. Dose and duration of cisplatin were adjusted for tumor size. After resection, good responders (90% or greater necrosis) underwent treatment with the same agents and poor responders were treated with alternative agents for longer duration. Minimum followup was 24 months (mean, 111 months; range, 24-235 months). Estimated Kaplan-Meier survival at 10 years was 82% and event-free survival was 79%. Forty-one patients (77%) had a good histologic response and 92% (49 of 53) underwent limbsparing procedures. Local recurrence occurred in two patients (4%). These results compared favorably with those reported in the current literature.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Intraarterial Chemotherapy for Extremity Osteosarcoma and MFH in Adults

Hugate

Wilkins

Kelly

et al. 2008

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

show abstract

“…At least 1 surgical complication was reported in approximately 55% of patients in some studies, although the majority were the result of the technical procedures. 1 Minor surgical complications were noted in 12 patients in the current study whereas aseptical loosening was reported to occur in 3 patients (14%), none of whom required the removal of the prosthesis. The rate of complications requiring intervention was 23% in the COSS-82 study.…”

Section: Discussionmentioning

confidence: 85%

“…At the time of last follow-up, we had not encountered any fatal doxorubicin-induced cardiotoxicity compared with other studies. 1 Cardiac failure had not been reported in any of the current study patients because the cumulative dose of doxorubicin had not exceeded 300 mg/m 2 at the time of last-follow-up. No patient had died of treatment-related complications.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The feasibility of neoadjuvant high‐dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with nonmetastatic high grade localized osteosarcoma

Arpacı

Ataergin

Özet

et al. 2005

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe primary and secondary objectives of the current study were to improve the ≥ 90% tumor necrosis rate and assess the toxicity profile of the neoadjuvant high‐dose chemotherapy (HDC) regimen, respectively.METHODSTwenty‐two patients with AJCC Stage IIB high‐grade osteosarcoma were included in the current study. Two cycles of an induction chemotherapy regimen including cisplatin, doxorubicin, and ifosfamide followed by HDC and autologous peripheral blood stem cell support or transplantation (APBSCT) were given. After engraftment was achieved, the patients underwent limb‐sparing surgery (LSS) followed by three to six cycles of postoperative chemotherapy depending on the tumor necrosis rate.RESULTSThe median follow‐up, the total duration of treatment, and the time to surgery were 23.7 months, 5.96 months, and 3.03 months, respectively. The necrosis rate was at least 90% in 82% of the cases. The 3‐year overall survival (OS) and disease‐free survival (DFS) rates were 83% and 70%, respectively. Leukopenia, anemia, thrombocytopenia, nausea and emesis, and mucositis were the most frequent Grade 3 and Grade 4 toxicities (according to the National Cancer Institute Common Toxicity Criteria [version 2.0]) of induction, high‐dose, and adjuvant chemotherapies. At the time of last follow‐up, no patient had died of chemotherapeutic toxicity. LSS was performed in all patients. Surgery‐related complications were reported in 3 of 22 patients. Functional scoring results were excellent in eight patients, good in nine patients, fair in two patients, and poor in three patients.CONCLUSIONSThe results of the current Phase II study suggest that neoadjuvant HDC provides a greater than 90% necrosis rate with acceptable toxicity. A short duration of therapy and the feasibility of LSS in all patients are additional advantages of this approach. Cancer 2005. © 2005 American Cancer Society.

show abstract

MiR‐329 suppresses osteosarcoma development by downregulating Rab10

Jiang

Liu

et al. 2016

FEBS Letters

View full text Add to dashboard Cite

MiR‐329 has been proved to be a tumor suppressor gene in various malignancies, however, its role in osteosarcoma remains elusive. We found that miR‐329 is remarkably downregulated in osteosarcoma tissues and relates to advanced stages. MiR‐329 is able to inhibit osteosarcoma cell proliferation, promote apoptosis, and induce G0/G1 cell cycle arrest. In addition, miR‐329 also suppresses wound‐healing and migration ability of osteosarcoma cells and inhibits tumorigenicity in vivo. Rab10 was identified as a target of miR‐329 in osteosarcoma and mediates its biofunction. These findings may shed light to the understanding of tumor development in osteosarcoma.

show abstract

Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report

Cited by 381 publications

References 40 publications

Intraarterial Chemotherapy for Extremity Osteosarcoma and MFH in Adults

Intraarterial Chemotherapy for Extremity Osteosarcoma and MFH in Adults

The feasibility of neoadjuvant high‐dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with nonmetastatic high grade localized osteosarcoma

MiR‐329 suppresses osteosarcoma development by downregulating Rab10

Contact Info

Product

Resources

About